Clinical Trial

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-12 -> 2029-12 2026-05-28
minor Completion pushed: 2029-12 -> 2030-12 2026-05-28
Trial Details
NCT Number NCT05700448
Lead Sponsor CStone Pharmaceuticals
Conditions Extranodal NK/T-cell Lymphoma
Enrollment 150 participants
Start Date 2027-06
Primary Completion 2029-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-27